| __timestamp | BioCryst Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 129764000 |
| Thursday, January 1, 2015 | 1896000 | 152008000 |
| Friday, January 1, 2016 | 2699000 | 209620000 |
| Sunday, January 1, 2017 | 1702000 | 241786000 |
| Monday, January 1, 2018 | 471000 | 315264000 |
| Tuesday, January 1, 2019 | 4101000 | 359466000 |
| Wednesday, January 1, 2020 | 1676000 | 524272000 |
| Friday, January 1, 2021 | 7264000 | 470515000 |
| Saturday, January 1, 2022 | 6594000 | 483669000 |
| Sunday, January 1, 2023 | 4661000 | 577065000 |
| Monday, January 1, 2024 | 580235000 |
Unleashing the power of data
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for BioMarin Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, BioMarin consistently reported a significantly higher cost of revenue, peaking at approximately $577 million in 2023, compared to BioCryst's $4.7 million. This stark contrast highlights BioMarin's expansive operations and market reach. However, BioCryst's leaner cost structure, with a 10-year average cost of revenue around $3.1 million, suggests a more streamlined approach. Notably, BioCryst's cost efficiency improved by over 3,700% from 2014 to 2023, while BioMarin's costs increased by 345%. These insights underscore the diverse strategies employed by biotech firms in managing operational expenses, reflecting their unique market positions and growth trajectories.
Cost of Revenue Trends: Merck & Co., Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Merck & Co., Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Novartis AG vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Pfizer Inc. vs BioMarin Pharmaceutical Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Sarepta Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Catalent, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Cytokinetics, Incorporated
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.